2 news items
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PASG
14 May 24
that Dose 1 PBFT02 achieved robust CSF progranulin levels, sustained for up to six months post-treatment (n=2), the company plans to continue studying
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PASG
4 Mar 24
Sustained momentum in global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for frontotemporal dementia (FTD
- Prev
- 1
- Next